CTx-1301-Dexmethylphenidate 12.5 mg (titration only) for ADHD
This study is completed in the United States. It is testing CTx-1301-Dexmethylphenidate 12.5 mg (titration only) for ADHD.
ADHD, Attention-deficit Hyperactivity, ...DrugFrom 6 Years to 17 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether CTx-1301-Dexmethylphenidate 12.5 mg (titration only) may be useful for children experiencing ADHD.
What would participation involve?
Participants may receive CTx-1301-Dexmethylphenidate 12.5 mg (titration only), attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: August 1, 2023
Recruitment status
Completed
Enrollment listed in the registry
103
Sponsor
Cingulate Therapeutics
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 6 Years to 17 Years
Official registry ID
NCT05286762
Official title
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multi-center, Fixed-dose, Parallel Group Efficacy and Safety in Pediatrics (6-17) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT05286762. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 24 sites
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Site status: Not listed — confirm with the team
Meridien Research
Maitland, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Site status: Not listed — confirm with the team
Atlanta Center for Medical Research
Atlanta, Georgia
Site status: Not listed — confirm with the team
Sisu Bhr, Llc
Springfield, Massachusetts
Site status: Not listed — confirm with the team
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan
Site status: Not listed — confirm with the team
St Charles Psychiatric Associates & Midwest Research Group
Saint Charles, Missouri
Site status: Not listed — confirm with the team
Center for Psychiatry and Behavioral Medicine. Inc.
Las Vegas, Nevada
Site status: Not listed — confirm with the team
Hassman Research Institute
Berlin, New Jersey
Site status: Not listed — confirm with the team
Icahn School of Medicine at Mount Sinai
New York, New York
Site status: Not listed — confirm with the team
Dayton Clinical Research
Dayton, Ohio
Site status: Not listed — confirm with the team
SP Research PLLC
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Summit Research Network, LLC
Portland, Oregon
Site status: Not listed — confirm with the team
Coastal Pediatric Associates
Charleston, South Carolina
Site status: Not listed — confirm with the team
Coastal Carolina Research Center
North Charleston, South Carolina
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee
Site status: Not listed — confirm with the team
Access Clinical Trials Inc.
Nashville, Tennessee
Site status: Not listed — confirm with the team
BioBehavioral Research of Austin
Austin, Texas
Site status: Not listed — confirm with the team
Gadolin Research
Beaumont, Texas
Site status: Not listed — confirm with the team
Houston Clinical Trials
Bellaire, Texas
Site status: Not listed — confirm with the team
FutureSearch Trials
Dallas, Texas
Site status: Not listed — confirm with the team
Red Oak Psychiatry Associates, PA
Houston, Texas
Site status: Not listed — confirm with the team
Family Psychiatry of The Woodlands
Woodland, Texas
Site status: Not listed — confirm with the team
Clinical Research Partners LLC
Petersburg, Virginia
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with adhd; age range: From 6 Years to 17 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Cingulate Therapeutics, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
